Business
CBD Life Sciences, Inc. Expands Footprint With Proposed Strategic Acquisition of Interest in Two New York Cannabis Dispensaries
CBD Life Sciences, Inc. Expands Footprint With Proposed Strategic Acquisition of Interest in Two New York Cannabis Dispensaries.
About this update from Cbd Life Sciences Inc.
[{"type":"text","content":"The targeted acquisitions are estimated to have a business value of approximately $14 millionSCOTTSDALE, AZ / ACCESSWIRE / August 27, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leading innovator in the CBD industry, is pleased to announce that the company is in advanced discussions to acquire a strategic minority interest in two state-licensed cannabis dispensaries located in Upstate New York and Long Island. This acquisition represents a significant growth milestone for CBD Life Sciences, Inc. as the company continues to expand its presence in the rapidly growing cannabis market. The dispensary in Upstate New York is projected to open its doors by November 1, 2024, with the Long Island location expected to follow in early 2025.Strategic Expansion for Increased Market PenetrationWith the legal cannabis market in New York expected to exceed $4.2 billion by 2027, this strategic acquisition positions CBD Life Sciences, Inc. to capture a substantial share of this lucrative market. The company's investment in these dispensaries is anticipated to generate significant revenue growth, with projections indicating a potential increase of 20% in annual revenue by the end of the first year of operations.Strengthening Investor ConfidenceCBD Life Sciences, Inc. has consistently demonstrated its commitment to delivering value to its shareholders. The acquisition aligns with the company's growth strategy, which focuses on expanding its footprint in key markets, increasing revenue streams, and enhancing profitability. With an anticipated 15% increase in EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) following the dispensary openings, the company is well positioned to deliver sustainable returns to its investors.Leadership's Vision"Our expansion into the New York cannabis market marks a pivotal moment for CBD Life Sciences, Inc.," said Lisa Nelson, President, and CEO of CBDL. "We are excited about the potential these dispensaries bring, not only in terms of revenue growth but also in solidifying our position as a key player in the cannabis industry. Our commitment to our investors remains our top priority, and we believe this acquisition will drive significant value in the coming years."About CBD Life Sciences, Inc.The CBD Vault Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. The CB...